CAMP4 Therapeutics Q2 net loss widens to $33.5 million on non-cash charge
CAMP4 Therapeutics reported a second-quarter 2026 net loss of $33.5 million, up from $12.6 million a year earlier, mainly due to a $20.9 million non-cash loss from a change in fair value of a derivative tranche liability tied to its September 2025 private placement. Revenue rose to $1.8 million from $1.5 million, and the company said its cash is sufficient to fund planned activities through the end of 2028.
Key points
- Net loss for the quarter ended June 30, 2026, was $33.5 million, compared with $12.6 million a year earlier.
- Research and collaboration revenue was $1.8 million, up from $1.5 million; R&D expenses were $10.8 million and G&A expenses were $4.3 million.
- Cash and cash equivalents were $86.4 million at June 30, 2026, down from $109.5 million at December 31, 2025; the company closed a second private placement tranche raising $50.1 million after quarter-end.
- Regulatory clearance was received in Australia and Argentina for a Phase 1/2 trial of CMP-002, with trial launch expected in Q4 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.